StockNews.AISignal intelligence
OS Therapies Incorporated · NYSE · Healthcare
Browse public OSTX signals with their source context and measured market impact. Open any signal for its permanent analysis page.
OS Therapies announced an initial warrant inducement closing, raising $7.2M gross and $7M UK R&D tax credits, extending runway toward key 2026 milestones. The company intends 4Q2026 BLA submission to FDA and CMAAs to MHRA/EMA/TGA for Herlystic, with potential Priority Review Voucher monetization, depending on regulatory outcomes.
View signal analysisOS Therapies reports statistically significant three-year overall survival gains with OST-HER2 in osteosarcoma patients post-resection, with 72.7% versus 45.8% historical control. WHO approved the brand name Herlystic, and OSTX aims to file early market access submissions in the US, UK, Europe, and Australia in Q4 2026. A Rare Pediatric Disease voucher could add strategic value if granted.
View signal analysisOS Therapies announces key leadership hires as it gears up for Herlystic commercialization across the U.S., U.K., and Europe. The company outlines regulatory steps, targeting UK CMAA in Q4 2026 via Project Orbis, with a US BLA under Accelerated Approval and European CMAAs to follow, supported by VAT refunds and delayed payables that bolster near-term liquidity.
View signal analysisOS Therapies reports OST-HER2 delivering a meaningful survival signal in metastatic osteosarcoma, with 2-year OS at 75% vs 60% (p=0.034). Three-year OS data, key for conditional approvals, is slated for early Q4 2026, with EMA/TGA alignment and multiple regulatory meetings including a US FDA Type B discussion. If the data meet expectations, OSTX could advance an accelerated approval pathway in major markets, providing a near-term catalyst for the stock.
View signal analysisOS Therapies (OSTX) expects to submit conditional Marketing Authorization Applications to both the U.K.'s MHRA and the EMA by the end of Q1 2026. This milestone could enhance OSTX's competitive positioning and is critical for future revenue growth if approvals are granted.
View signal analysisOSTX shares are down significantly following positive biomarker data from its Phase 2b trial, which bolsters its upcoming Biologics License Application. Regulatory approval is targeted for early 2026 in key markets, yet current bearish momentum and recent stock performance raises concerns for investors.
View signal analysis